Abstract
Aims Current risk prediction tools are not accurate enough to identify most individuals at high coronary risk. On the other hand, oxidized low-density lipoproteins (ox-LDLs) and miRNAs are actively involved in atherosclerosis. Our aim was to examine the association of ox-LDL-induced miRNAs with coronary artery disease (CAD), and to assess their predictive capacity of future CAD.
Methods and results Human endothelial and vascular smooth muscle cells were treated with oxidized or native LDLs (nLDL), and their miRNA expression was measured with the miRNA 4.0 array, and analyzed with moderated t-tests. Differently expressed miRNAs and others known to be associated with CAD, were examined in serum samples of 500 acute myocardial infarction (AMI) patients and 500 healthy controls, and baseline serum of 117 incident CAD cases and c 485 randomly-selected cohort participants (case-cohort). Both were developed within the REGICOR AMI Registry and population cohorts from Girona. miRNAs expression in serum was measured with custom OpenArray plates, and analyzed with fold change (age and sex-paired case-control) and survival models (case-cohort). Improvement in discrimination and reclassification by miRNAs was assessed. Twenty-one miRNAs were up- or down-regulated with ox-LDL in cell cultures. One of them, 1 (has-miR-122-5p, fold change=4.85) was upregulated in AMI cases. Of the 28 known CAD-associated miRNAs, 11 were upregulated in AMI cases, and 1 (hsa-miR-143-3p, hazard ratio=0.56 [0.38-0.82]) was associated with CAD incidence and improved reclassification.
Conclusion We identified 2 novel miRNAs associated with ox-LDLs (hsa-miR-193b-5p and hsa-miR-1229-5p), and 1 miRNA that improved reclassification of healthy individuals (hsa-miR-143-3p).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Spain’s Ministry of Science and Innovation through the Carlos III Health Institute, co-financed with European Union ERDF funds [INTRASALUD PI11/01801, PI15/00064, Network for Prevention and Health Promotion in primary Care RedIAPP RD06/0018, RD12/0005, CIBERCV CB16/11/00229, CIBERESP CB06/02/0029, CIBEROBN CB06/03/0028]; by the BBVA Foundation [PR-16-BIO-CAR-0041] by the Health Departament of the Generalitat de Catalunya, through the Agency for Health Quality and Assessment of Catalonia (AQUAS) and the Strategic Plan for research and health innovation (PERIS) [SLT002/16/ 00145, SLT006/17/00029], and by the Catalan Agency for Management of University and Research Grants (AGAUR) [2017 SGR 222].
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
The data used in this study is available from the authors on reasonable request
